Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
Regorafenib is a valuable treatment option for metastatic colorectal cancer patients who have
progressed after prior standard treatments. Prior progression-free survival data suggest that
there could be a distinct subgroup of patients that may benefit from regorafenib. The aim of
this study is to identify predictive biomarker of regorafenib in terms of its efficacy.